e-learning
resources
Paris 2018
Sunday, 16.09.2018
New developments in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis
K. Murphy (Boys Town, United States of America), R. Noble (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)
Source:
International Congress 2018 – New developments in the treatment of asthma
Session:
New developments in the treatment of asthma
Session type:
Thematic Poster
Number:
1026
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Murphy (Boys Town, United States of America), R. Noble (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America). Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis. 1026
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy
Source: International Congress 2017 – COPD management
Year: 2017
Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003
Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Circulating desmosine as a biomarker of azithromycin treatment response: a
post hoc
analysis of the COLUMBUS randomised controlled trial
Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018
Year: 2018
Cost-effectiveness of tiotropium versus salmeterol: A trial-based analysis followed by a model-based extrapolation
Source: Annual Congress 2011 - Understanding the burden of chronic respiratory diseases: what decision makers need to know
Year: 2011
Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose
Source: Eur Respir J 2002; 20: Suppl. 38, 396s
Year: 2002
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002
Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003
Use of a novel Bayesian borrowing statistical method to assess efficacy of mepolizumab in adolescents
Source: Virtual Congress 2020 – Paediatric asthma
Year: 2020
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study
Source: International Congress 2018 – Asthma and drugs
Year: 2018
Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept